BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38290657)

  • 1. Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling.
    Wang B; Zhang X; Li ZS; Wei C; Yu RZ; Du XZ; He YJ; Ren Y; Zhen YW; Han L
    Cancer Lett; 2024 Mar; 585():216665. PubMed ID: 38290657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypomethylated PDZK1 acts as a tumorigenic gene in glioma by interacting with AKT1.
    Ren X; Deng D; Xiang S; Feng J
    Aging (Albany NY); 2024 Apr; 16(8):7174-7187. PubMed ID: 38669103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YANK2 activated by Fyn promotes glioma tumorigenesis via the mTOR-independent p70S6K activation pathway.
    Shi Y; Cheng Y; Wang W; Tang L; Li W; Zhang L; Yuan Z; Zhu F; Duan Q
    Sci Rep; 2024 May; 14(1):10507. PubMed ID: 38714727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.
    Wang J; Ren D; Sun Y; Xu C; Wang C; Cheng R; Wang L; Jia G; Ren J; Ma J; Tu Y; Ji H
    J Cell Mol Med; 2020 Apr; 24(7):3931-3947. PubMed ID: 32126150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT1 Promotes Tumorigenesis and Metastasis by Directly Phosphorylating Hexokinases.
    Yu Y; Wang S; Wang Y; Zhang Q; Zhao L; Wang Y; Wu J; Han L; Wang J; Guo J; Xue J; Dong F; Zhang JH; Zhang L; Liu Y; Shi G; Zhang X; Li Y; Li J
    J Cell Biochem; 2024 Jun; ():. PubMed ID: 38860522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo‑like kinase 4 promotes tumorigenesis and induces resistance to radiotherapy in glioblastoma.
    Wang J; Zuo J; Wang M; Ma X; Gao K; Bai X; Wang N; Xie W; Liu H
    Oncol Rep; 2019 Apr; 41(4):2159-2167. PubMed ID: 30816483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
    Tian X; Zhou D; Chen L; Tian Y; Zhong B; Cao Y; Dong Q; Zhou M; Yan J; Wang Y; Qiu Y; Zhang L; Li Z; Wang H; Wang D; Ying G; Zhao Q
    Cell Death Dis; 2018 Jan; 9(2):54. PubMed ID: 29352113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fraxetin down-regulates polo-like kinase 4 (PLK4) to inhibit proliferation, migration and invasion of prostate cancer cells through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway.
    Ma Z; Sun Y; Peng W
    Bioengineered; 2022 Apr; 13(4):9345-9356. PubMed ID: 35387563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study.
    Zhong S; Zhang Z; Guo Z; Yang W; Dou G; Lv X; Wang X; Ge J; Wu B; Pan X; Wang H; Mou Y
    Bioengineered; 2022 May; 13(5):12003-12020. PubMed ID: 35603567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
    Zhang Z; Wang Z; Huang K; Liu Y; Wei C; Zhou J; Zhang W; Wang Q; Liang H; Zhang A; Wang G; Zhen Y; Han L
    Cancer Lett; 2019 Feb; 443():91-107. PubMed ID: 30529153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase.
    Ding Z; Liang J; Li J; Lu Y; Ariyaratna V; Lu Z; Davies MA; Westwick JK; Mills GB
    PLoS One; 2010 Mar; 5(3):e9910. PubMed ID: 20361045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt Serine/Threonine Kinase 1 Regulates de Novo Fatty Acid Synthesis through the Mammalian Target of Rapamycin/Sterol Regulatory Element Binding Protein 1 Axis in Dairy Goat Mammary Epithelial Cells.
    Zhang T; Huang J; Yi Y; Zhang X; Loor JJ; Cao Y; Shi H; Luo J
    J Agric Food Chem; 2018 Feb; 66(5):1197-1205. PubMed ID: 29323924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-overexpression of RIOK1 and AKT1 as a prognostic risk factor in glioma.
    Wang Y; Xie X; Li S; Zhang D; Zheng H; Zhang M; Zhang Z
    J Cancer; 2021; 12(19):5745-5752. PubMed ID: 34475988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Paradox of Akt-mTOR Interactions.
    Vadlakonda L; Dash A; Pasupuleti M; Anil Kumar K; Reddanna P
    Front Oncol; 2013; 3():165. PubMed ID: 23802099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.
    Guan R; Kang Z; Li L; Yan X; Gao T
    PLoS One; 2024; 19(1):e0295813. PubMed ID: 38194422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA-Dependent Regulation of AKT1 Phosphorylation.
    Frederick MI; Siddika T; Zhang P; Balasuriya N; Turk MA; O'Donoghue P; Heinemann IU
    Cells; 2022 Feb; 11(5):. PubMed ID: 35269443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.
    Byrne DP; Clarke CJ; Brownridge PJ; Kalyuzhnyy A; Perkins S; Campbell A; Mason D; Jones AR; Eyers PA; Eyers CE
    Biochem J; 2020 Jul; 477(13):2451-2475. PubMed ID: 32501498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells.
    Xu Z; Sun Y; Wang D; Sun H; Liu X
    Cancer Cell Int; 2020; 20():236. PubMed ID: 32536824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.